MARC Record from marc_columbia

LEADER: 05128cam a2200505 a 4500
001 8212162
005 20221201060413.0
008 100826t20102010dcuab b 100 0 eng c
020 $a0309153328
020 $a9780309153324
029 1 $aAU@$b000046489752
035 $a(OCoLC)ocn658581476
035 $a(NNC)8212162
035 $a(OCoLC)658581476
035 $a8212162
040 $aYDXCP$cYDXCP$dNRZ$dUPM$dUBY$dCDX
042 $apcc
043 $an-us---
050 4 $aR853.C55$bT73 2010
082 04 $a610.72$222
245 00 $aTransforming clinical research in the United States :$bchallenges and opportunities : workshop summary /$cRebecca A. English, Yeanwoo Lebovitz, and Robert B. Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
260 $aWashington, D.C. :$bNational Academies Press,$c[2010], ©2010.
300 $axvii, 131 pages :$billustrations (some color), color maps ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references (p. 103-105).
530 $aAlso available in Open Book format via the National Academies Press home page.
505 0 $aIntroduction -- The state of clinical research in the United States: an overview -- Challenges in clinical research -- Clinical trials in cardiovascular disease -- Clinical trials in depression -- Clinical trials in cancer -- Clinical trials in diabetes -- Building a robust clinical trials infrastructure.
520 $a"An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise."--Publisher's description.
650 0 $aClinical trials$zUnited States$vCongresses.
650 0 $aClinical trials$xResearch$zUnited States$vCongresses.
650 0 $aClinical trials$xGovernment policy$zUnited States$vCongresses.
650 12 $aClinical Trials as Topic.$0https://id.nlm.nih.gov/mesh/D002986
650 22 $aBiomedical Research.$0https://id.nlm.nih.gov/mesh/D035843
650 22 $aResearch Design.$0https://id.nlm.nih.gov/mesh/D012107
650 22 $aEvidence-Based Medicine.$0https://id.nlm.nih.gov/mesh/D019317
651 2 $aUnited States.$0https://id.nlm.nih.gov/mesh/D014481
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
700 1 $aEnglish, Rebecca A.$0http://id.loc.gov/authorities/names/no2010177259
700 1 $aLebovitz, Yeonwoo.$0http://id.loc.gov/authorities/names/no2010177280
700 1 $aGiffin, Robert B.$0http://id.loc.gov/authorities/names/no96041278
710 2 $aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.$0http://id.loc.gov/authorities/names/no2007051854
710 2 $aNational Academies Press (U.S.)$0http://id.loc.gov/authorities/names/no2003001840
856 41 $uhttp://www.nap.edu/catalog.php?record_id=12900
852 00 $boff,sci$hR853.C55$iT365 2010